← Product Code [GMQ](/submissions/MI/subpart-d%E2%80%94serological-reagents/GMQ) · K955136 # RPR CARD TEST KIT (K955136) _Remel, L.P. · GMQ · Jul 29, 1996 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GMQ/K955136 ## Device Facts - **Applicant:** Remel, L.P. - **Product Code:** [GMQ](/submissions/MI/subpart-d%E2%80%94serological-reagents/GMQ.md) - **Decision Date:** Jul 29, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.3820 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Device Story The REMEL RPR Card Test is an in vitro diagnostic assay used to detect reagin antibodies in human serum or plasma. The test utilizes an antigen suspension that reacts with reagin antibodies present in the patient sample; the presence of antibodies is indicated by macroscopic flocculation. The test is performed by laboratory personnel in a clinical setting. Results are interpreted visually by the technician to determine reactive or nonreactive status, with reactive samples often titered to determine the endpoint. The test aids in the screening for syphilis infection. Clinical utility is supported by comparison to established RPR and USR antigens, with results correlated against patient history of Treponema pallidum infection and treatment status. ## Clinical Evidence Bench-only study. Two batches of REMEL RPR antigen (in-house and LEE Laboratories) were evaluated against BD RPR and Difco USR antigens. Testing included reactive and nonreactive samples with documented Treponema pallidum infection stages and treatment histories. Results were compared against MHA-TP. No statistically significant differences in performance were observed between REMEL antigens and predicate antigens. Discrepant samples were resolved via blinded re-testing at a secondary site, showing consistency with reference methods. No clinical prospective/retrospective patient outcome data provided. ## Technological Characteristics In vitro diagnostic card test. Employs macroscopic flocculation principle using RPR antigen suspension. Manual visual interpretation. No electronic components, software, or energy sources. Sterilization not applicable. ## Regulatory Identification Treponema pallidum nontreponemal test reagents are devices that consist of antigens derived from nontreponemal sources (sources not directly associated with treponemal organisms) and control sera (standardized sera with which test results are compared) used in serological tests to identify reagin, an antibody-like agent, which is produced from the reaction of treponema microorganisms with body tissues. The identification aids in the diagnosis of syphilis caused by microorganisms belonging to the genus Treponema and provides epidemiological information on syphilis. ## Predicate Devices - BD RPR antigen - Difco USR antigen ## Reference Devices - MHA-TP test ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K955136 JUL 29 1996 Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Blvd. Rockville, MD 20850 RE: 510(k) Submission for RPR Card Test Kit Summary of Safety and Effectiveness November 8, 1995 Dear Sir: In accordance with 21 CFR Chapter 1, Subpart E, Sec. 807.93, and as part of the 510(k) submission for the RPR Liquid Controls, the following information is provided. Reasonable assurance that this device is safe and effective was determined through the use of valid scientific nonclinical investigations including in vitro studies. The results of these studies are summarized in the attached Technical Insert. This device is effective when tested under the conditions for its intended use. Each test kit contains a technical insert which provides adequate directions and precautions for use. Lastly, each insert contains information on the limitations and the performance characteristics of the test (including relative sensitivity and specificity data) when used according to the directions. SUMMARY OF SAFETY AND EFFECTIVENESS DATA: Raw performance data Intended use of the product Limitations of the product Relative sensitivity and specificity data Directions for procedure 510(k) Submission Should there be any questions concerning this matter, please contact me at (706)736-6011. Sincerely, David A. Wall Manager, Immunodiagnostics {1} # REMEL RPR CARD TEST ## PERFORMANCE CHARACTERISTICS ### University of Texas Dr. Beth Hartwell & Michigan Department of Public Health Mr. Harlan Stiefel Two batches of RPR antigen were tested at the Univ. of Texas in comparison to the BD RPR antigen. Antigen #1 was made by REMEL and evaluated by the CDC before use in determining its performance characteristics. This material was considered "Satisfactory" by the CDC (copy of report enclosed). Antigen #2 was made for REMEL at LEE Laboratories in Grayson, GA and was also tested and deemed "Satisfactory" by the CDC. Both materials were evaluated since REMEL would like the option to make or purchase this antigen as needed. The REMEL manufactured RPR antigen (Ag#1) was tested at U. of Texas without any significant discrepancies. It was tested vs the BD RPR antigen, and MHA-TP (for all reactives). Patient genders were documented for all specimens. Patient gender did not affect the outcome of the tests. Many of the reactive samples were titered for both RPR antigens and there was no statistically significant difference in performance between the two. Additionally, data is provided on several of the reactive samples which includes stage of infection with Treponema pallidum and history of treatment. Reactive results are consistent with the history of treatment and staging of illness. The LEE Labs RPR antigen (Ag#2) was tested at both the Univ. of Texas vs the BD RPR antigen and Michigan Dept. of Health. vs the Difco USR antigen. Again, patient genders were recorded. Gender had no affect on the outcome of the tests. Also, stage of infection with Treponema pallidum and historical treatment on many of the reactive samples were recorded. All reactive samples were also tested vs the MHA-TP test with results consistent with the history of treatment and staging of illness. There were a number of the reactive samples tested at the U. of Texas that were read as nonreactive with the Ag#2 and reactive (undiluted endpoint titer) with the BD Ag. Repeat testing of the same samples with the same material at the U. of Texas yielded the same results. Because the same antigen (#2) was used at the Michigan site without any significant # of discrepancies, the remainder of the U. of Texas discrepant samples along with 12 known reactive samples and 12 known nonreactive samples were sent blinded to Michigan. Michigan reported results which were consistent between the known results at Texas and between RPR and USR. Additionally, except with only a couple of samples, the RPR results were consistent with the USR test in the discrepant samples. The raw data is enclosed and a summary of the testing follows. 81/10 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GMQ/K955136](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GMQ/K955136) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com